Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.36 |
| ▸ | GFPT1 | Q06210 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20981993 | 1.00 | HCAR2 (0.36) | HCAR2KEAP1NFE2L2GFPT1 | |
| SCHEMBL17048371 | 1.00 | HCAR2 (0.36) | HCAR2KEAP1NFE2L2GFPT1 | |
| SCHEMBL17048269 | 1.00 | HCAR2 (0.36) | HCAR2KEAP1NFE2L2GFPT1 | |
| SCHEMBL17048385 | 0.95 | PRKCA (0.38) | HCAR2KEAP1NFE2L2 | |
| SCHEMBL17048266 | 0.95 | HCAR2 (0.34) | HCAR2KEAP1NFE2L2 | |
| SCHEMBL15824044 | 0.83 | HCAR2 (0.52) | HCAR2KEAP1NFE2L2GFPT1 | |
| SCHEMBL15824042 | 0.83 | HCAR2 (0.52) | HCAR2KEAP1NFE2L2GFPT1 | |
| SCHEMBL15824045 | 0.83 | HCAR2 (0.52) | HCAR2KEAP1NFE2L2GFPT1 | |
| SCHEMBL17699005 | 0.77 | HCAR2 (0.59) | HCAR2KEAP1NFE2L2GFPT1 | |
| SCHEMBL17699004 | 0.77 | HCAR2 (0.59) | HCAR2KEAP1NFE2L2GFPT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3110789-B1 | DERIVATIVES OF POLYHYDROXY COMPOUNDS | RATIOPHARM GMBH (DE) | 2019-05-22 | — | — | EP | disclosed |
| US-9796659-B2 | Derivatives of polyhydroxy compounds | RATIOPHARM GMBH (DE) | 2017-10-24 | — | — | US | disclosed |
| US-9796659-B2 | Derivatives of polyhydroxy compounds | RATIOPHARM GMBH (DE) | 2017-10-24 | — | — | US | disclosed |
| US-20170001945-A1 | DERIVATIVES OF POLYHYDROXY COMPOUNDS | RATIOPHARM GMBH (DE) | 2017-01-05 | — | — | US | disclosed |
| US-20170001945-A1 | DERIVATIVES OF POLYHYDROXY COMPOUNDS | RATIOPHARM GMBH (DE) | 2017-01-05 | — | — | US | disclosed |
| EP-3110789-A1 | DERIVATIVES OF POLYHYDROXY COMPOUNDS | ratiopharm GmbH (DE) | 2017-01-04 | — | — | EP | disclosed |
| WO-2015128488-A1 | DERIVATIVES OF POLYHYDROXY COMPOUNDS | RATIOPHARM GMBH (DE) | 2015-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170001945-A1 | DERIVATIVES OF POLYHYDROXY COMPOUNDS | TPMT, FH, FAH | HCAR2 11/4885KEAP1 588/4885NFE2L2 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.